drugset / Trial / NCT05152797
Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer
Phase 1/2
Not yet recruiting
91 enrolled
Women's Hospital School Of Medicine Zhejiang University
Qilu Hospital of Shandong University · collabSun Yat-sen University · collabTongji Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Prospective, multicenter, single-arm, open label, interventional basket trial to evaluate autologous tumor-infiltrating lymphocytes (TILs) infusion followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparation for the treatment of patients with advanced or metastatic refractory gynecological cancer including cervical, ovarian, endometrial and breast carcinoma.
Timeline
- Start
- 2022-01-01
- Primary completion
- 2024-01-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Tumor Infiltrating Lymphocytes | Cell therapy | — | — |
Indications
No indication recorded.